Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital. They showed that within a 5-year period, this therapy could provide a favorable prognosis without severe non-hematological side effects. These findings could provide new insights into a novel treatment option for patients with high-risk neuroblastoma.
- Mount Sinai researchers build models using machine learning technique to enhance predictions of COVID-19 outcomes
- Eliminating microplastics in wastewater directly at the source
- Vermont’s BIPOC drivers are most likely to have a run-in with police, study shows
- Many parents say teens with anxiety, depression may benefit from peer confidants at school
- Where COVID-19 hit hardest, sudden deaths outside the hospital increased